Your browser doesn't support javascript.
loading
Circulating beta-hydroxybutyrate levels in advanced heart failure with reduced ejection fraction: Determinants and prognostic impact.
Monzo, Luca; Kovar, Jan; Borlaug, Barry A; Benes, Jan; Kotrc, Martin; Kroupova, Katerina; Jabor, Antonin; Franekova, Janka; Melenovsky, Vojtech.
Afiliación
  • Monzo L; Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic.
  • Kovar J; Université de Lorraine, Centre d'Investigations Cliniques Plurithématique 1433 and Inserm U1116, CHRU Nancy, FCRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
  • Borlaug BA; Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic.
  • Benes J; Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
  • Kotrc M; Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic.
  • Kroupova K; Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic.
  • Jabor A; Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic.
  • Franekova J; Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic.
  • Melenovsky V; Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic.
Eur J Heart Fail ; 2024 Jun 10.
Article en En | MEDLINE | ID: mdl-38853653
ABSTRACT

AIMS:

Patients with heart failure (HF) display metabolic alterations, including heightened ketogenesis, resulting in increased beta-hydroxybutyrate (ß-OHB) formation. We aimed to investigate the determinants and prognostic impact of circulating ß-OHB levels in patients with advanced HF and reduced ejection fraction (HFrEF). METHODS AND

RESULTS:

A total of 867 patients with advanced HFrEF (age 57 ± 11 years, 83% male, 45% diabetic, 60% New York Heart Association class III), underwent clinical and echocardiographic examination, circulating metabolite assessment, and right heart catheterization (n = 383). The median ß-OHB level was 64 (interquartile range [IQR] 33-161) µmol/L (normal 0-74 µmol/L). ß-OHB levels correlated with increased markers of lipolysis (free fatty acids [FFA]), higher natriuretic peptides, worse pulmonary haemodynamics, and lower humoral regulators of ketogenesis (insulin/glucagon ratio). During a median follow-up of 1126 (IQR 410-1781) days, there were 512 composite events, including 324 deaths, 81 left ventricular assist device implantations and 107 urgent cardiac transplantations. In univariable Cox regression, increased ß-OHB levels (T3 vs. T1 hazard ratio [HR] 1.39, 95% confidence interval [CI] 1.13-1.72, p = 0.002) and elevated FFA levels (T3 vs. T1 HR 1.39, 95% CI 1.09-1.79, p = 0.008) were both predictors of a worse prognosis. In multivariable Cox analysis evaluating the simultaneous associations of FFA and ß-OHB levels with outcomes, only FFA levels remained significantly associated with adverse outcomes.

CONCLUSIONS:

In patients with advanced HFrEF, increased plasma ß-OHB correlate with FFA levels, worse right ventricular function, greater neurohormonal activation and other markers of HF severity. The association between plasma ß-OHB and adverse outcomes is eliminated after accounting for FFA levels, suggesting that increased ß-OHB is a consequence reflecting heightened lipolytic state, rather than a cause of worsening HF.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Eur J Heart Fail Asunto de la revista: CARDIOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: República Checa

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Eur J Heart Fail Asunto de la revista: CARDIOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: República Checa